Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
As the country moves to value-based care, the number of alternative payment models is growing, and many practices are participating in more than one. Are they having trouble balancing multiple models?
It depends on the model. So, OCM [Oncology Care Model] involves so much of the patient mix of OCM practices and because of the care transformation components of the program from the get-go it’s been an area of focus for anyone that’s in OCM.
In some of the other programs, like BPCI [Bundled Payments for Care Improvement] Advanced, there is intersection and overlap with other programs, like the ACO [accountable care organization] program, for example. And those models, thought, BPCI is a great avenue to incent specialists within a primary care model, like an ACO. So, it does differ.
But from an OCM perspective we see that participants are very focused and with the movement toward downside risk in OCM, for those practices that make that choice this fall, definitely more focus on OCM because of that. Whereas a one-sided model, it’s a different beginning than being in a risk-based model.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Dual Therapy Appears to Benefit Patients With Pulmonary Fibrosis, Pulmonary Hypertension
May 15th 2025The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.
Read More